Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma

被引：12

作者：

Amiot, Aurelien ^{[1
,2
,3
]}

Jooste, Valerie ^{[4
]}

Gagniere, Charlotte ^{[1
,2
,3
]}

Levy, Michael ^{[1
]}

Copie-Bergman, Christiane ^{[2
,5
,6
]}

Dupuis, Jehan ^{[7
]}

Le Baleur, Yann ^{[1
]}

Belhadj, Karim ^{[7
]}

Sobhani, Iradj ^{[1
]}

Haioun, Corinne ^{[2
,6
,7
]}

Bouvier, Anne-Marie ^{[4
]}

Delchier, Jean-Charles ^{[1
,2
]}

机构：

[1] Grp Hosp Henri Mondor Albert Chennevier, APHP, Dept Gastroenterol, Creteil, France

[2] Univ Paris Est Creteil UPEC, Fac Med, Creteil, France

[3] EC2M3 EA7375 Unit, Creteil, France

[4] Univ Burgundy, Univ Hosp Dijon, Digest Canc Registry Burgundy, INSERM,U866, Dijon, France

[5] Grp Hosp Henri Mondor Albert Chennevier, APHP, Dept Pathol, Creteil, France

[6] INSERM, Unit UMR S 955, Creteil, France

[7] Grp Hosp Henri Mondor Albert Chennevier, APHP, Lymphoid Malignancies Unit, Creteil, France

来源：

LEUKEMIA & LYMPHOMA | 2017年 / 58卷 / 09期

关键词：

MALT; rituximab; alkylating agents; rituximab plus chlorambucil; t(11; 18) translocation; INFLAMMATORY-BOWEL-DISEASE; B-CELL LYMPHOMA; MALT-LYMPHOMA; HELICOBACTER-PYLORI; FOLLOW-UP; RISK; NEOPLASMS; RITUXIMAB; CANCERS; SYSTEM;

D O I：

10.1080/10428194.2017.1283033

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To assess the risk of second primary malignancy (SPM) in patients with gastric mucosa-associated lymphoid tissue (MALT) Lymphoma (GML), we included 175 patients with GML in the present study. The incidence of SPM in the general population, used for reference, was determined from the French network of cancer registries. During the 1442.9 patient-years of follow-up, 29 patients were diagnosed with incident SPM, including five patients diagnosed with gastric cancer (20.1/1000 patient-years). An increased incidence of SPM was observed in patients with GML (standardized incidence ratios [SIR]: 1.71 [1.14-2.45]) compared to the general French population especially for gastric cancer (SIR: 16.1 [5.19-37.56]). This elevated risk of SPM was significantly increased only in patients treated with immuno/chemotherapy but not in patients treated with Helicobacter pylori eradication alone. Long-term follow-up of patients with GML is mandatory even in patients who have achieved complete remission.

引用

页码：2057 / 2064

页数：8

共 30 条

[1] Interactions Between the Host Innate Immune System and Microbes in Inflammatory Bowel Disease [J].